The National Healthcare Board has announced that it is actively considering the introduction of a strict statutory price cap (a maximum price) on rapid-acting insulin analogues.
Pharmaceutical sector representatives are bracing for the most significant federal government intervention in decades, following an eight-year period of sharply rising prices and chronically low patient switching rates. Research indicates that many diabetic patients suffer from a form of purchasing inertia, staying with premium brand-name drugs due to high informational barriers and fear of switching to biosimilar alternatives.
The Board's Chairperson promised to step in because the private pharmaceutical market is "fundamentally failing to deliver equitable healthcare outcomes." Average monthly out-of-pocket costs for a pack of five insulin pens have surged by 95% over the past decade, leaving uninsured families spending upwards of 40% of their net disposable income on this life-critical medication.
However, healthcare economists have cautioned against this heavy-handed approach. They warn that artificial price caps could severely damage supply, leading to manufacturers redirecting distribution to other countries, underinvesting in critical R&D, and ultimately leaving patients with fewer and lower-quality treatment options.
With reference to Extract C, discuss the likely microeconomic effects of introducing a maximum price cap in the private pharmaceutical market on manufacturers (producers) and patients (consumers). Include a supply and demand diagram in your answer.
